AIkido Pharma Inc. kajeno e tlalehile ntlafatso ea ts'ebetso ea tlhahiso ea lithethefatsi tsa eona tsa kankere ea pancreatic, DHA-dFdC, e nang le tumello ho tloha Univesithing ea Texas e Austin. Khampani e boetse e tlalehile ka tlhahiso ea patent e eketsehileng ea U.S. e koahelang sethethefatsi sena, le ho hlahlelloa ha kopo e tsoelang pele ea patent e reretsoeng ho atolosa tšireletso ea patent likarolong tse ling tsa moriana.
Mabapi le ts'ebetso ea tlhahiso, Khampani e tlalehile nts'etsopele e atlehileng ea mekhoa e mecha bakeng sa tlhahiso e lekantsoeng le ho itšehla thajana ha motsoako oa bohlokoa oa bohareng ha ho etsoa DH-dFdC. Khampani e se e entse konteraka e 'ngoe le mokhatlo oa eona oa tlhahiso ea konteraka, Parimer Scientific, ho sebelisa mokhoa o mocha oa ho hlahisa limiligrama tse likete tse 'maloa tsa moriana bakeng sa ho sebelisoa lithutong tsa ntlafatso ea tlhahiso le botsitso. Khampani e boetse e tlaleha hore Ofisi ea Patent ea U.S. e sa tsoa fana ka Patent e ncha ea U.S. No. 11,219,633, e fanang ka tšireletso e eketsehileng ea thepa ea mahlale bakeng sa motsoako oa lithethefatsi. Nako ea tokelo ea molao e lebelletsoe ho tsoela pele ho fihlela Mots'eanong oa 2035 ka tefo ea litefiso tse hlokahalang tsa tlhokomelo. Pele ho phano ea tokelo ea molao, Khampani e ile ea fana ka tumello ea ho kenya kopo ka nako ea ts'ebetso ea patent, U.S. Serial No. 17/539,682, moo ho tla lateloa likopo tse ling tse amanang le likarolo tse fapaneng tsa moriana le tlhahiso.
Anthony Hayes, CEO oa AIkido, o itse, "Ts'ebetso ena e ncha e hatela pele ho nts'etsopele ea sethethefatsi sa rona sa mofets'e oa pancreatic mme e lokela ho lumella tlhahiso ea moriana ka tekanyo ea khoebo ka theko e tlase. Hape ke thabetse hore re ka tsoela pele ho tlaleha katoloso ea setša sa patent. ”
Richard T. Pace, Mong’a le Rasaense e Moholo oa Parimer Scientific, o itse, “Mokhoa o sa tsoa ntlafatsoa oa tlhahiso ke mohato o moholo oa tsoelopele bakeng sa theknoloji ena e ncha. Ke lumela hore e tla fokotsa litšenyehelo ka yuniti ka 'ngoe 'me ka nako e ts'oanang e eketse lihlahisoa tsa lihlahisoa. "
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- With respect to manufacturing process, the Company reported the successful development of a new means for the scaled production and isolation of the key intermediate compound in the manufacture of DH-dFdC.
- Anthony Hayes, CEO of AIkido, stated, “This new process significant step forward in the development of our pancreatic cancer drug and should permit production of the drug on a commercial scale at a lower cost.
- The Company has now executed a further contract with its contract manufacturing organization, Parimer Scientific, to employ the new process to produce several thousand milligrams of the drug for use in formulation development and stability studies.
